• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

避孕药贴中活性成分释放的数学建模:以Ortho Evra(®)为例进行研究

Mathematical modeling of the release of active ingredients from a contraceptive patch: ortho evra(®) as a case study.

作者信息

Trujillo-de Santiago Grissel, Patricio Sáenz-Collins Carlos, García-Arellano Lizette, Moisés Álvarez Mario

机构信息

FEMSA-Biotechnology Center, Monterrey Tech (Centro de Biotecnología-FEMSA, Tecnológico de Monterrey). Ave. Eugenio Garza Sada 2501 sur. Col. Tecnológico, Monterrey, Nuevo León, México.C.P.64849.

出版信息

Iran J Pharm Res. 2014 Winter;13(1):39-48.

PMID:24734055
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3985262/
Abstract

Contraceptive patches have become a frequently used contraceptive method. We present a mathematical model that describes the serum concentration profiles of Norelgestromin (NGMN) and Ethinylestradiol (EE) released from the contraceptive patch Ortho Evra(®). We propose a simple one-compartment model based on pharmacokinetics data reported in previous studies. The model assumes a time-dependent release rate and a first order elimination rate for each of the active ingredients contained in the patch. The model was applied to noncompliance scenarios, such as total and partial detachment of the patch or prolonged use without patch replacement. The proposed model adequately describes the clinically observed evolution of NGMN and EE in serum. Predictions from the model were successfully validated using reported experimental data of serum concentrations of NGMN and EE. This simple model can be a valuable tool to predict pharmacokinetic profiles in diverse scenarios such us non-compliance situations. Alternatively, the model can be conveniently adapted to anticipate the effect of variations on patch characteristics such as differences in contact area, doses, materials, among others.

摘要

避孕贴片已成为一种常用的避孕方法。我们提出了一个数学模型,该模型描述了从避孕贴片Ortho Evra(®)释放的诺孕酯(NGMN)和炔雌醇(EE)的血清浓度曲线。我们基于先前研究报告的药代动力学数据提出了一个简单的单室模型。该模型假设贴片中所含每种活性成分的释放速率随时间变化且消除速率为一级。该模型被应用于不依从的情况,例如贴片完全或部分脱落,或延长使用而不更换贴片。所提出的模型充分描述了临床上观察到的血清中NGMN和EE的变化情况。使用报告的NGMN和EE血清浓度实验数据成功验证了该模型的预测结果。这个简单的模型可以成为预测各种情况下药代动力学曲线的有价值工具,比如不依从情况。另外,该模型可以方便地进行调整,以预测贴片特性变化的影响,如接触面积、剂量、材料等方面的差异。

相似文献

1
Mathematical modeling of the release of active ingredients from a contraceptive patch: ortho evra(®) as a case study.避孕药贴中活性成分释放的数学建模:以Ortho Evra(®)为例进行研究
Iran J Pharm Res. 2014 Winter;13(1):39-48.
2
Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites.含去氧孕烯炔雌醇的避孕贴片(依伴依/欧伴依)在四个应用部位的药代动力学。
Br J Clin Pharmacol. 2002 Feb;53(2):141-6. doi: 10.1046/j.0306-5251.2001.01532.x.
3
Pharmacokinetic overview of Ortho Evra/Evra.Ortho Evra/Evra的药代动力学概述
Fertil Steril. 2002 Feb;77(2 Suppl 2):S3-12. doi: 10.1016/s0015-0282(01)03261-7.
4
Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise.在高温、高湿及运动条件下,通过避孕贴片(炔诺孕酮炔雌醇片(Ortho Evra/Evra))给药的炔诺孕酮和炔雌醇的药代动力学。
J Clin Pharmacol. 2001 Dec;41(12):1301-9. doi: 10.1177/00912700122012887.
5
Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches.来自两片连续避孕贴片的诺孕酯和炔雌醇的药代动力学。
J Clin Pharmacol. 2001 Nov;41(11):1232-7. doi: 10.1177/00912700122012788.
6
Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: A double-blind, randomized, bioequivalence and adhesion study in healthy women.比较一种含有新型黏合成分的经皮避孕贴与依维莫司贴剂:一项在健康女性中进行的双盲、随机、生物等效性和黏附性研究。
Contraception. 2020 Apr;101(4):276-282. doi: 10.1016/j.contraception.2019.12.012. Epub 2020 Jan 11.
7
Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life.一项在健康女性中进行的随机、双盲、两向交叉生物等效性和黏附性研究,比较新来源黏合成分的经皮避孕贴在货架期末与 EVRA 贴剂在货架期初的情况。
Int J Clin Pharmacol Ther. 2022 Jan;60(1):67-78. doi: 10.5414/CP204034.
8
Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants.
Contraception. 2001 Nov;64(5):287-94. doi: 10.1016/s0010-7824(01)00273-6.
9
Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.经皮炔雌醇/去氧孕烯炔雌醇:其在激素避孕中的应用综述
Treat Endocrinol. 2003;2(3):191-206. doi: 10.2165/00024677-200302030-00005.
10
Transdermal contraception.经皮避孕
Semin Reprod Med. 2001 Dec;19(4):373-80. doi: 10.1055/s-2001-18645.

本文引用的文献

1
Mathematical modeling of simultaneous drug release and in vivo absorption.药物释放和体内吸收的同步数学建模。
Int J Pharm. 2011 Oct 10;418(1):130-41. doi: 10.1016/j.ijpharm.2010.12.044. Epub 2011 Jan 13.
2
Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users.关于经皮避孕药使用者血栓栓塞结局的扩展病例对照研究结果。
Contraception. 2010 May;81(5):408-13. doi: 10.1016/j.contraception.2009.12.009. Epub 2010 Jan 22.
3
Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism.
含 30 微克炔雌醇的左炔诺孕酮与依托孕烯皮下埋植剂和含 30 微克炔雌醇的左炔诺孕酮口服避孕药的上市后研究与非致死性静脉血栓栓塞症相关。
Contraception. 2010 Jan;81(1):16-21. doi: 10.1016/j.contraception.2009.07.004.
4
Transdermal hormonal contraception: benefits and risks.经皮激素避孕:益处与风险。
Am J Obstet Gynecol. 2007 Aug;197(2):134.e1-6. doi: 10.1016/j.ajog.2007.04.027.
5
Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.与使用含诺孕酯和35微克炔雌醇的口服避孕药的使用者相比,避孕透皮贴剂使用者发生非致命性静脉血栓栓塞风险的进一步研究结果。
Contraception. 2007 Jul;76(1):4-7. doi: 10.1016/j.contraception.2007.03.003. Epub 2007 May 11.
6
One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.在绝经后女性中对递送低剂量雌二醇 - 醋酸炔诺酮的连续联合透皮基质贴片进行的一年期子宫内膜安全性评估。
Maturitas. 2007 Jun 20;57(2):171-81. doi: 10.1016/j.maturitas.2007.01.001. Epub 2007 Feb 20.
7
Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.性腺功能减退男性中,透皮睾酮贴片与透皮睾酮凝胶的稳态药代动力学、代谢及变异性比较
J Sex Med. 2005 Mar;2(2):213-26. doi: 10.1111/j.1743-6109.2005.20231.x.
8
Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception.
Eur J Obstet Gynecol Reprod Biol. 2005 Aug 1;121(2):202-10. doi: 10.1016/j.ejogrb.2005.01.021.
9
Current status and future potential of transdermal drug delivery.透皮给药的现状与未来潜力
Nat Rev Drug Discov. 2004 Feb;3(2):115-24. doi: 10.1038/nrd1304.
10
The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy.提高对每周一次的避孕透皮系统(欧丝蕊)的依从性对避孕效果的影响。
Contraception. 2004 Mar;69(3):189-95. doi: 10.1016/j.contraception.2003.10.006.